Atea Pharmaceuticals, Inc. (AVIR) — 10-Q Filings
All 10-Q filings from Atea Pharmaceuticals, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Atea's Q3 Loss Widens Amid Increased R&D for HCV Program
— Nov 12, 2025 Risk: high
Atea Pharmaceuticals, Inc. (AVIR) reported a net loss of $42.049 million for the three months ended September 30, 2025, an increase from the $31.151 million net -
Atea Narrows Q2 Loss to $45.2M Amid R&D Cost Cuts
— Aug 7, 2025 Risk: high
Atea Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company's net lo -
Atea Pharma Files Q1 2025 10-Q, Notes Merck Deal
— May 12, 2025 Risk: medium
Atea Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operations, including information r -
Atea Pharmaceuticals Files Q3 2024 10-Q
— Nov 7, 2024 Risk: medium
Atea Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the thi -
Atea Pharmaceuticals Files Q2 2024 10-Q
— Aug 7, 2024 Risk: medium
Atea Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business opera -
Atea Pharmaceuticals Files 10-Q for Period Ending March 31, 2024
— May 14, 2024 Risk: low
Atea Pharmaceuticals, Inc. (AVIR) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Atea Pharmaceuticals, Inc. filed a 10-Q report for the period en
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX